A triple whammy Drugs like semaglutide (the active ingredient in Ozempic and Wegovy) have greatly improved obesity treatment in recent years, allowing people to lose significantly more weight than they typically would with diet and exercise alone
Importantly, there were no dose-dependent signals for pancreatitis or thyroid C-cell tumors in the human data, though the standard rodent-derived thyroid risk noted on semaglutide and tirzepatide labels will presumably carry over to retatrutide's prescribing information pending further analysis
In an M&A context, the existence of a pending first-filer ANDA with a Paragraph IV certification against the targets drug is highly material
Specifically, the primary clinical limitation remains the absence of large-scale Randomized Controlled Trials (RCTs) in PAH patients, particularly those without diabetes
Some analysts expect the FDA decision could come in the second quarter
It has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA), nor has it received a positive opinion from the European Medicines Agency (EMA)
.png)
